Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: A 10-year experience

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 1127-1135

  Pearson, Glen J ^a,b   Olson, Kari L ^c   Panich, Nicole E ^a   Majumdar, Sumit R ^a,b   Tsuyuki, Ross T ^a   Gilchrist, Dawna M ^a,b   Damani, Ali ^a   Francis, Gordon A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiovascular risk factors; Dyslipidemia; Outcomes; Pharmacotherapy; Secondary prevention

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CERIVASTATIN; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK REDUCTION; TERTIARY HEALTH CARE; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; LIPIDS; OUTPATIENT CLINICS, HOSPITAL; PATIENT DISCHARGE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 56849085454     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Anderson KM, Castelli WP, Levy D. 1987. Cholesterol and mortality: 30 years of follow up from the Framingham study. JAMA, 257:2176-80.
2. Baigent C, Keech A, Kearney PM, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet, 366:1267-78.
3. Castelli WP, Garrison RJ, Wilson PWF, et al. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA, 256:2835-8.
4. Cooke CE, Hammerash WJ Jr. 2006. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. Clin Ther, 28:591-9.
5. Fodor JG, Frolich JJ, Genest Jr. JJG, et al. 2000. Recommendations for the management and treatment of dyslipidemia. CMAJ, 162:1441-7.
6. Garcia Ruiz FJ, Marin Ibanez A, Perez-Jiminez F, et al. 2004. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics, 22(Suppl 3):1-12.
7. Gavish D, Leibovitz E, Elly I, et al. 2002. Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients. Isr Med Assoc J, 4:694-7.
8. Grundy SM, Pasternak R, Greenland P, et al. 1999. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation, 100:1481-92.
9. Harris DE, Gipson GW, Pearson TA, et al. 1998. Lipid lowering in a multidisciplinary clinic compared with primary physician management, Am J Cardiol, 81:929-33.
10. Heart and Stroke Foundation of Canada. 1999. The changing face of heart disease and stroke in Canada 2000. Laboratory Centre for Disease Control, Health Canada, Statistics Canada, Canadian Institute for Health Information, Canadian Cardiovascular Society, Canadian Stroke Society, Heart Stroke Foundation of Canada; Ottawa, Canada [online]. Accessed on March 15, 2008. URL: http://www.hc-sc.gc.ca/hpb/lcdc/bcrdd/hdsc2000/pdf/ card2ke.pdf.
11. Koren MJ, Hunninghake DB. 2004. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. J Am Coll Card, 44:1772-9.
12. Majumdar SR, Gurwitz JH, Soumerai SB. 1999. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med, 14:711-7.
13. McPherson R, Frohlich J, Fodor J, et al. 2006. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol, 22:913-27.
14. Murray CJ, Lopez AD. 1997. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 349:1436-42.
15. [NCEP ATP III] National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106:3143-421.
16. Neaton JD, Blackburn H, Jacobs D, et al. 1992. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Arch Intern Med, 152:1490-500.
17. Olson KL, Rasmussen J, Sandhoff BG, et al. 2005. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med, 165:49-54.
18. Pearson TA, Laurora I, Chu H, et al. 2000. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med, 160:459-67.
19. Salant P, Dillman D. 1994. How to conduct your own survey. New York: John Wiley and Sons.
20. Schrott HG, Bittner V, Vittinghoff E, et al. 1997. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA, 277:1281-6.
21. Shaffer J, Wexler LF. 1995. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Arch Intern Med, 155:2330-5.
22. Stacy TA, Egger A. 2006. Results of a retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm, 12:745-51.
23. Stamler J, Wentworth D, Neaton J. 1996. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256:2823-7.
24. Taher TH, Dzavik V, Reteff EM, et al. 2002. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol, 89:390-4.
25. Wilson TW, Quest DW, Wilson M, et al. 1999. A cardiovascular risk factor reduction clinic. Can J Cardiol, 15:887-91.
26. Yates S, Annis L, Pippins J, et al. 2001. Does a lipid clinic increase compliance with National Cholesterol Education Program treatment guidelines? Report of a case-matched control study. South Med J, 94:907-9.